Celltrion’s Vegzelma Becomes Fourth US-Approved Bevacizumab

Estimated US Market Launch Date Is H1 2023

 
• By Rosalind Rei

Celltrion’s Vegzelma earns a long-awaited USFDA approval. The oncology biosimilar will be up against established bevacizumab products from Amgen and Pfizer as well as recent newcomer Amneal.

Label that reads "FDA APPROVED" on top a portion of the American Flag
• Source: Shutterstock

More from Biosimilars

More from Products